Robbins LLP urges URGN investors with substantial losses to inquire about the class action lawsuit against UroGen Pharma Ltd
UroGen engages in the development and commercialization of solutions for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.